- Home
- VRCA vs NMTC Comparison
VRCA vs NMTC Comparison
Compare VRCA & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | NMTC |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 31.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRCA | NMTC |
|---|---|---|
| Price | $8.28 | $0.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | N/A | ★ $2.23 |
| AVG Volume (30 Days) | ★ 402.7K | 198.6K |
| Earning Date | 11-14-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,829,000.00 | $6,629,051.00 |
| Revenue This Year | $373.65 | $162.84 |
| Revenue Next Year | N/A | $26.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 234.73 | 69.00 |
| 52 Week Low | $3.28 | $0.40 |
| 52 Week High | $9.82 | $1.39 |
Technical Indicators
Market Signals| Indicator | VRCA | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 63.22 | 48.47 |
| Support Level | $7.82 | $0.55 |
| Resistance Level | $9.78 | $0.75 |
| Average True Range (ATR) | 1.17 | 0.05 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 65.21 | 62.18 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.